ArticleBMC musculoskeletal disorders2026
Characterization of pain-related mechanisms and bone destruction in mild and severe monoiodoacetate-induced hip arthropathy in rats.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study aimed to characterize pain-related mechanisms and the bone-destructive environment in mild and severe monoiodoacetate (MIA)-induced hip arthropathy in rats, with particular focus on features relevant to rapidly destructive coxarthrosis.
methodsRats were divided into sham, low-dose MIA, and high-dose MIA groups (n = 12 per group) and received intra-articular injections of saline, low-dose MIA, or high-dose MIA, respectively. Pain-related behaviors were assessed using von Frey and weight-bearing tests. Radiological and histological changes were evaluated using microcomputed tomography and the Osteoarthritis Research Society International scoring system. The proportion of calcitonin gene-related peptide (CGRP)-immunoreactive dorsal root ganglion (DRG) neurons and the number of ionized calcium-binding adaptor molecule 1 (Iba1)-immunoreactive microglia in the spinal dorsal horn were quantified immunohistochemically. Synovial mRNA expression of tumor necrosis factor-α (Tnf-α) and receptor activator of nuclear factor-kappa B ligand (Rankl), as well as osteoclast-like multinucleated cells in the femoral head, were also quantified.
resultsThe high-dose MIA group showed significantly greater mechanical hypersensitivity and reduced weight-bearing capacity than the low-dose MIA and sham groups. This group also demonstrated more severe joint destruction, higher OARSI scores, a higher proportion of CGRP-immunoreactive DRG neurons, and an increased number of Iba1-immunoreactive microglia in the spinal dorsal horn. Synovial Tnf-α and Rankl mRNA expression levels were significantly increased in the high-dose MIA group compared with those in the sham and low-dose MIA groups. These changes were accompanied by an increased number of osteoclast-like multinucleated cells and bone resorption cavities compatible with Howship's lacunae in the femoral head.
conclusionsHigh-dose MIA-induced hip arthropathy was characterized by more severe pain-related behavior, a higher proportion of CGRP-immunoreactive DRG neurons, an increased number of Iba1-immunoreactive microglia in the spinal dorsal horn, and a more pronounced osteoclast-associated bone-destructive environment than low-dose MIA-induced hip arthropathy. These findings suggest that the high-dose MIA model exhibits several experimental features relevant to rapidly destructive hip disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.